Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/10/29 23:13:29」(JST)

wiki en

Bucillamine is an antirheumatic agent developed from tiopronin. It is mainly used in Japan and Korea. Activity is mediated by the two thiol groups that the molecule contains. Research done in USA showed positive transplant preservation properties.^[1]

References

^ Amersi, F.; Nelson, S. K.; Shen, X. D.; Kato, H.; Melinek, J.; Kupiec-Weglinski, J. W.; Horwitz, L. D.; Busuttil, R. W.; Horwitz, M. A. (2002). "Bucillamine, a Thiol Antioxidant, Prevents Transplantation-Associated Reperfusion Injury" (pdf). Proceedings of the National Academy of Sciences. 99 (13): 8915–8920. PMC 124398 . PMID 12084933. doi:10.1073/pnas.132026099.

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 膜性腎症の原因および診断 causes and diagnosis of membranous nephropathy

English Journal

Drug-induced kidney disease: a study of the Japan Renal Biopsy Registry from 2007 to 2015.

Yokoyama H1, Narita I2, Sugiyama H3, Nagata M4, Sato H5, Ueda Y6, Matsuo S7.
Clinical and experimental nephrology.Clin Exp Nephrol.2016 Oct;20(5):720-730. Epub 2015 Nov 21.
INTRODUCTION: The Japan Renal Biopsy Registry (J-RBR) was started in 2007 by the Committee for the Standardization of Renal Pathological Diagnosis and the Committee for the Kidney Disease Registry of the Japanese Society of Nephrology. The purpose of this report is to clarify drug-induced kidney dis
PMID 26590949

New and Pipeline Drugs for Gout.

Keenan RT1,2, Schlesinger N3.
Current rheumatology reports.Curr Rheumatol Rep.2016 Jun;18(6):32. doi: 10.1007/s11926-016-0579-7.
Gout is the most common inflammatory arthropathy in the western world. Affecting millions and accounting for lost wages, increased health care costs, and significant disability, it remains a burden for those afflicted, their families, and the health care system. Despite the availability of a number
PMID 27097819

[DMARDs (Focusing on iguratimod)].

Ito S.
Nihon rinsho. Japanese journal of clinical medicine.Nihon Rinsho.2016 Jun;74(6):948-54.
Conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) other than methotrexate (MTX: anchor csDMARDs) are effective for single use, reinforcement of MTX, biologics and induction and maintenance of biologics-free condition. Newly developed iguratimod (IGU) does not suppress immunolo
PMID 27311184

Japanese Journal

ブシラミン内服により生じたInterstitial Granulomatous Drug Reactionの1例 (特集薬疹・薬物障害)

皮膚科の臨床 59(1), 9-12, 2017-01
NAID 40021060891

Drug-induced kidney disease: a study of the Japan Renal Biopsy Registry from 2007 to 2015

Clinical and experimental nephrology 20(5), 720-730, 2016-10
NAID 120005867133

症例報告ブシラミン投与により発症した乾癬型薬疹と思われる1例

臨床皮膚科 = Japanese journal of clinical dermatology 70(10), 761-766, 2016-09
NAID 40020958519

Related Pictures

★リンクテーブル★

リンク元

「ブシラミン」

Bucillamine
Names
	IUPAC name 2-[(2-Methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid[citation needed]
Identifiers
CAS Number	65002-17-7 R ;
3D model (JSmol)	Interactive image; Interactive image;
ChemSpider	2365 ;
KEGG	D01809 ;
MeSH	bucillamine
PubChem CID	2459; 656604 R; 636373 S;
UNII	R80LRA5WTF ;
	InChI InChI=1S/C7H13NO3S2/c1-7(2,13)6(11)8-4(3-12)5(9)10/h4,12-13H,3H2,1-2H3,(H,8,11)(H,9,10) Key: VUAFHZCUKUDDBC-UHFFFAOYSA-N ;
	SMILES CC(C)(S)c(:[o]):[nH]C(CS)c(:[o]):[oH] ; CC(C)(S)C(=O)NC(CS)C(O)=O ;
Properties
Chemical formula	C7H13NO3S2
Molar mass	223.31 g·mol−1
log P	1.032
Acidity (pKa)	3.012
Basicity (pKb)	10.985
Pharmacology
ATC code	M01CC02 (WHO)
Related compounds
Related Alkanoic acids	Acetylcysteine; Glycylglycine; Iminodiacetic acid; Nitrilotriacetic acid; N-Oxalylglycine; Tiopronin; Oxalyldiaminopropionic acid; gamma-Glutamylcysteine;
Related compounds	N-Acetylglycinamide;
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	Infobox references

　　[★]

英: bucillamine
商: ブシラミン、ブシラント、ブシレート、リマチル、レマルク
関: 抗リウマチ薬

[1] Amersi, F.; Nelson, S. K.; Shen, X. D.; Kato, H.; Melinek, J.; Kupiec-Weglinski, J. W.; Horwitz, L. D.; Busuttil, R. W.; Horwitz, M. A. (2002). "Bucillamine, a Thiol Antioxidant, Prevents Transplantation-Associated Reperfusion Injury" (pdf). Proceedings of the National Academy of Sciences. 99 (13): 8915–8920. PMC 124398 . PMID 12084933. doi:10.1073/pnas.132026099.

v t e Specific antirheumatic products / DMARDs (M01C)
Quinolines	Oxycinchophen
Gold preparations	Sodium aurothiomalate Sodium aurothiosulfate Auranofin Aurothioglucose Aurotioprol
Other	Penicillamine #/Bucillamine Chloroquine #/Hydroxychloroquine Leflunomide Sulfasalazine # antifolate (Methotrexate #) thiopurine (Azathioprine) #
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

匿名

検索

案内

案内

bucillamine